Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
8.72
+0.05 (0.58%)
At close: Nov 4, 2024, 4:00 PM
8.80
+0.08 (0.92%)
Pre-market: Nov 5, 2024, 9:08 AM EST
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 296 employees as of December 31, 2023. The number of employees increased by 28 or 10.45% compared to the previous year.
Employees
296
Change (1Y)
28
Growth (1Y)
10.45%
Revenue / Employee
$446,155
Profits / Employee
-$671,497
Market Cap
1.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 296 | 28 | 10.45% |
Dec 31, 2022 | 268 | 121 | 82.31% |
Dec 31, 2021 | 147 | 93 | 172.22% |
Dec 31, 2020 | 54 | 25 | 86.21% |
Dec 31, 2019 | 29 | - | - |
Related Stocks
Company Name | Employees |
---|---|
OPKO Health | 3,930 |
MiMedx Group | 895 |
Aurinia Pharmaceuticals | 300 |
Zymeworks | 278 |
Evolus | 273 |
Collegium Pharmaceutical | 197 |
CARGO Therapeutics | 116 |
Mesoblast | 73 |
ARQT News
- 16 hours ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - GlobeNewsWire
- 14 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
- 18 days ago - Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - GlobeNewsWire
- 5 weeks ago - New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types - GlobeNewsWire
- 6 weeks ago - FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over - GlobeNewsWire
- 2 months ago - Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely - Seeking Alpha
- 2 months ago - Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire